Eli Lilly and Company (LLY) Wednesday said that the U.S. Food and Drug Administration (FDA) has approved a label update for Kisunla with a new dosing recommendation for adults with early symptomatic Alzheimer's disease (AD).
The new dosing recommendation is to start with a single vial and gradually increase dosing to the full 4 vials at month 4. The previous schedule was 2 vials a month for the initial 3 months and full 4-vials dose starting from the fourth month.
The new dosing schedule significantly lowered the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E), a kind of brain swelling, compared to the original dosing schedule.
Kinsula was approved by the FDA in July last year for adults with early symptomatic Alzheimer's disease.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.